The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) is a huge mover today! About 144,255 shares traded hands. Trillium Therapeutics Inc. (NASDAQ:TRIL) has declined 30.72% since April 27, 2016 and is downtrending. It has underperformed by 35.95% the S&P500.
The move comes after 6 months negative chart setup for the $63.07 million company. It was reported on Nov, 30 by Barchart.com. We have $7.37 PT which if reached, will make NASDAQ:TRIL worth $1.89 million less.
Analysts await Trillium Therapeutics Inc. (NASDAQ:TRIL) to report earnings on March, 8. They expect $-0.89 EPS, down 217.86% or $0.61 from last year’s $-0.28 per share. After $-0.78 actual EPS reported by Trillium Therapeutics Inc. for the previous quarter, Wall Street now forecasts 14.10% negative EPS growth.
According to Zacks Investment Research, “Trillium Therapeutics Inc. is an immuno-oncology company. It engages in developing therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP?Fc and a CD200 monoclonal antibody, which target two key immunoregulatory spathway that tumor cells exploit to evade the host immune system. Trillium Therapeutics Inc. is based in Canada.”
More recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: Marketwatch.com which released: “Trillium Therapeutics Inc.” on August 24, 2009. Also Etfdailynews.com published the news titled: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock” on June 23, 2015. Quotes.Wsj.com‘s news article titled: “News Trillium Therapeutics Inc.TRIL” with publication date: December 20, 2014 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.